Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C.

Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E620-7. Epub 2007 May 15.

2.

Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects.

Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Lush CW, Chen K, Lacerte C, Burns C, McKay R, Weyer C, Horowitz M.

Obesity (Silver Spring). 2007 May;15(5):1179-86.

3.

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C.

J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83. Epub 2007 May 15.

PMID:
17504894
4.

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.

Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M.

Diabetologia. 2005 May;48(5):838-48. Epub 2005 Apr 21.

PMID:
15843914
5.

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C.

Obesity (Silver Spring). 2009 Sep;17(9):1736-43. doi: 10.1038/oby.2009.184. Epub 2009 Jun 11.

6.

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

Obes Res. 2004 Apr;12(4):661-8.

7.
8.

The role of pramlintide for weight loss.

Dunican KC, Adams NM, Desilets AR.

Ann Pharmacother. 2010 Mar;44(3):538-45. doi: 10.1345/aph.1M210. Epub 2010 Feb 17. Review.

PMID:
20164472
9.

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

Diabetes Technol Ther. 2002;4(1):51-61.

PMID:
12017421
10.

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.

PMID:
15498087
11.

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

Singh-Franco D, Robles G, Gazze D.

Clin Ther. 2007 Apr;29(4):535-62. Review.

PMID:
17617279
12.

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C.

Metabolism. 2003 Dec;52(12):1638-42.

PMID:
14669170
13.

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.

PMID:
14737746
14.

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

Metabolism. 2002 May;51(5):636-41.

PMID:
11979398
15.

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

Diabetes Care. 2002 Apr;25(4):724-30.

PMID:
11919132
16.

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.

Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.

Int J Obes (Lond). 2008 Aug;32(8):1201-10. doi: 10.1038/ijo.2008.91. Epub 2008 Jun 17.

PMID:
18560368
17.

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O.

Diabetes Care. 2006 Oct;29(10):2189-95.

PMID:
17003291
18.
19.

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

Diabetes Care. 2003 Mar;26(3):784-90.

PMID:
12610038
20.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996

Supplemental Content

Support Center